PRECiSE 1 & 2
PRECiSE 1 and PRECiSE 2 were a series of multicenter, randomized, double-blind, placebo-controlled trials of the drug certolizumab pegol, a new anti-tumor necrosis factor (TNF) therapy currently in development for the treatment of Crohn’s disease, rheumatoid arthritis, and psoriasis
